生命科学资讯

Comanche gets $40M more to test its preeclampsia siRNA

Servier taps Insilico’s AI platform for early cancer R&D

Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash

AbbVie does T cell engager deal in China for Zelgen's DLL3-targeted drug

Vanda wins FDA approval for motion sickness drug

FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome

Biotech’s groove is back for 2026 as XBI surges on M&A and lower rates

Insilico caps the year with a soaring Hong Kong IPO

Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blocker

Federal judge blocks 340B drug pricing pilot ahead of Jan. 1 effective date

ASK Pharm makes China rights deal; Unicycive resubmits kidney drug after CRL

Nido Bio to wind down after underwhelming Phase 2 data

As gene editing tools multiply, the hunt for the final technology continues

Ultragenyx, Mereo crash on late-stage bone disease failure

Genmab terminates Phase 3 lung cancer asset that BioNTech ditched

CMS unveils Medicare coverage model for weight loss drugs

Biohaven’s ion channel drug fails again, this time in major depressive disorder

J&J axes eczema drug from $1.25B acquisition

Agios finally wins approval for Aqvesme in thalassemia

Sanofi to buy hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug